CAMBRIDGE, Mass. — Alnylam Pharmaceuticals, Inc. announced a series of strategic initiatives aimed at improving early diagnosis and care coordination for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed cause of heart failure.
The company is collaborating with Viz.ai and supporting a national effort led by the American Heart Association to address gaps in detection and treatment, with a focus on improving patient outcomes through earlier intervention and more coordinated care.
ATTR-CM remains significantly underrecognized despite advances in treatment, with many patients going undiagnosed for years. Alnylam said its approach is designed to shift diagnosis earlier and enable health systems to deliver consistent, high-quality care at scale.
“As a cardiologist, I’ve seen firsthand the devastating impact of diagnosing ATTR-CM too late,” said Sameer Bansilal, M.D., M.S., vice president and global TTR medical lead at Alnylam Pharmaceuticals. “This is a progressive disease where timing truly matters – earlier recognition can fundamentally change a patient’s course of disease. Alnylam’s leadership in ATTR amyloidosis is grounded not only in deep science, a robust R&D program, and strong clinical evidence, but in a commitment to enduring impact – improving how this disease is identified and managed in real-world care.”
As part of the initiative, Alnylam is partnering with Viz.ai to develop an AI-enabled care pathway designed to help clinicians identify ATTR-CM earlier and guide appropriate diagnostic evaluation and referrals. The system integrates an FDA-cleared echocardiography AI algorithm with electronic health record connectivity to support clinical workflows.
The collaboration includes the AWARE study, a prospective, multi-system effort evaluating how AI-based screening tools can be implemented in real-world clinical settings and their impact on diagnosis timelines and care coordination. The study is expected to launch at five pilot health systems later this year.
“When ATTR-CM is identified late, patients face the risk of disease progression and poorer outcomes,” said Tim Showalter, M.D., chief medical officer at Viz.ai. “By embedding AI-driven detection into everyday clinical workflows and pairing it with coordinated care pathways, this collaboration focuses on closing the gap between the first clinical signal and meaningful clinical action, so more patients are identified and connected to care sooner before irreversible damage has occurred.”
In parallel, Alnylam is supporting a three-year initiative led by the American Heart Association to strengthen systems of care for ATTR-CM. The program will bring together a 10-site cohort of multidisciplinary health systems to identify care gaps, share best practices, and scale effective models for diagnosis and treatment.
Participating centers will assess current care pathways across diagnosis, referral, treatment, and follow-up, with the goal of improving coordination and patient outcomes. Insights from the initiative are expected to be shared nationally to support broader improvements in care delivery.
Alnylam said the combined efforts reflect its broader strategy to address systemic challenges in ATTR-CM care, including underdiagnosis and fragmented treatment pathways, by leveraging artificial intelligence, real-world data, and large-scale healthcare partnerships.
